DE60220441D1 - Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) - Google Patents

Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)

Info

Publication number
DE60220441D1
DE60220441D1 DE60220441T DE60220441T DE60220441D1 DE 60220441 D1 DE60220441 D1 DE 60220441D1 DE 60220441 T DE60220441 T DE 60220441T DE 60220441 T DE60220441 T DE 60220441T DE 60220441 D1 DE60220441 D1 DE 60220441D1
Authority
DE
Germany
Prior art keywords
ppar
agents
human
acid derivatives
receptor alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60220441T
Other languages
English (en)
Other versions
DE60220441T2 (de
Inventor
Lindstedt Eva-Lotte Alstermark
Anna Christina Olsson
Lanna Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE60220441D1 publication Critical patent/DE60220441D1/de
Application granted granted Critical
Publication of DE60220441T2 publication Critical patent/DE60220441T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
DE60220441T 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) Expired - Fee Related DE60220441T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0104334 2001-12-19
SE0104334A SE0104334D0 (sv) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005744 WO2003051822A1 (en) 2001-12-19 2002-12-18 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)

Publications (2)

Publication Number Publication Date
DE60220441D1 true DE60220441D1 (de) 2007-07-12
DE60220441T2 DE60220441T2 (de) 2008-01-24

Family

ID=20286433

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60220441T Expired - Fee Related DE60220441T2 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
DE60214594T Expired - Lifetime DE60214594T2 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60214594T Expired - Lifetime DE60214594T2 (de) 2001-12-19 2002-12-18 Substituierte phenylpropionsäurederivate als agonisten für den humanen peroxisomproliferatoraktivierten rezeptor alpha (ppar)

Country Status (31)

Country Link
US (2) US7514471B2 (de)
EP (2) EP1458673B1 (de)
JP (4) JP3820249B2 (de)
KR (2) KR20040074094A (de)
CN (3) CN1293044C (de)
AR (2) AR038047A1 (de)
AT (2) ATE338743T1 (de)
AU (2) AU2002366315A1 (de)
BR (2) BR0214986A (de)
CA (2) CA2470491A1 (de)
CY (2) CY1106276T1 (de)
DE (2) DE60220441T2 (de)
DK (2) DK1458672T3 (de)
ES (2) ES2286310T3 (de)
HK (2) HK1068604A1 (de)
HU (2) HUP0402022A3 (de)
IL (3) IL162330A0 (de)
IS (2) IS7309A (de)
MX (2) MXPA04006003A (de)
MY (1) MY132565A (de)
NO (2) NO20043023L (de)
NZ (2) NZ533276A (de)
PL (2) PL370672A1 (de)
PT (2) PT1458673E (de)
RU (2) RU2300517C2 (de)
SE (1) SE0104334D0 (de)
SI (2) SI1458673T1 (de)
TW (2) TWI253444B (de)
UA (2) UA77460C2 (de)
WO (2) WO2003051821A1 (de)
ZA (2) ZA200404658B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
US7220880B2 (en) 2002-06-19 2007-05-22 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
MXPA04012686A (es) 2002-06-20 2005-03-23 Astrazeneca Ab Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP2287166A3 (de) 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Kondensierte Aryl- und Heteroarylderivate als Modulatoren des Metabolismus sowie Vorbeugung und Behandlung von damit zusammenhängenden Störungen
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
JP2007516267A (ja) * 2003-12-15 2007-06-21 イーライ リリー アンド カンパニー 選択的ペルオキシソーム増殖因子活性化受容体モジュレータ
KR20070050475A (ko) * 2004-08-11 2007-05-15 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노 안식향산 유도체
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
EP1893583B1 (de) 2005-05-31 2012-04-04 Pfizer Inc. Substituierte aryloxy-n-bicyclomethylacetamidverbindungen als vr1-antagonisten
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
TWI331523B (en) * 2005-12-08 2010-10-11 Nat Health Research Institutes Vinylsulfonate compounds
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
BR112013010157B1 (pt) 2010-11-08 2020-02-04 Albireo Ab iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
JO3301B1 (ar) * 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
CA3053418A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
JP2023504643A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069247A1 (de) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren
EP4188541A1 (de) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepin-verbindungen und ihre verwendung als gallensäuremodulatoren
EP4243831A1 (de) 2020-11-12 2023-09-20 Albireo AB Odevixibat zur behandlung von progressiver familiärer intrahepatischer cholestase (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
WO2023039276A1 (en) * 2021-09-13 2023-03-16 Curtails Llc Use of ibat inhibitors and antimicrobials for the treatment of diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266121C (de)
BE489216A (de) 1948-06-05 1900-01-01
US2928840A (en) 1958-11-26 1960-03-15 Us Vitamin Pharm Corp 3-(o-substituted phenyl) oxazolidinediones and process therefor
GB1081471A (en) 1963-09-13 1967-08-31 Stauffer Chemical Co Glycol amide derivatives and use thereof in controlling weed growth
US3244398A (en) 1963-10-28 1966-04-05 Scaramucci Domer Composite seat ball valve
AT307640B (de) 1970-06-18 1973-05-25 Richter Gedeon Vegyeszet Verfahren zur Herstellung von neuen 17-Aza-steroiden und deren Salzen
BE792364A (fr) 1971-12-06 1973-06-06 Basf Ag Derives de substitution du sulfonylglycolanilide
DE2349256C2 (de) 1973-10-01 1985-08-01 Basf Ag, 6700 Ludwigshafen 0-Alkylsulfonyl-glykolsäureanilide und diese enthaltende Herbizide
DE2828222A1 (de) 1978-06-28 1980-01-10 Bayer Ag Gegenmittel zum schutz von kulturpflanzen vor schaedigungen durch herbizide
US4735959A (en) 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
US5312924A (en) 1983-12-30 1994-05-17 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5216167A (en) 1983-12-30 1993-06-01 Dr. Karl Thomae Gmbh Phenylacetic acid benzylamides
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5958792A (en) 1995-06-07 1999-09-28 Chiron Corporation Combinatorial libraries of substrate-bound cyclic organic compounds
WO1999011606A2 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6410585B1 (en) 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
EP1030853A1 (de) 1997-11-12 2000-08-30 Ariad Pharmaceuticals, Inc. Neue inhibitoren von signal-transduction, sie enthaltende zusammensetzungen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
IL145732A0 (en) 1999-04-06 2002-07-25 Sankyo Co α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
AU3670900A (en) * 1999-04-08 2000-11-14 Sankyo Company Limited Substituted fused imidazole derivatives
US6620929B1 (en) 1999-04-14 2003-09-16 University Of British Columbia 1,3-Dipolar cycloadditions to polypyrrolic macrocycles
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP2001261612A (ja) * 2000-03-22 2001-09-26 Mitsui Chemicals Inc カテコールプロピオン酸誘導体およびそれを有効成分として含有する核内レセプター作動薬
JPWO2002044130A1 (ja) * 2000-11-29 2004-04-02 杏林製薬株式会社 置換カルボン酸誘導体
AU2002222552A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
JP2004529097A (ja) 2001-02-15 2004-09-24 ファイザー・プロダクツ・インク Ｐｐａｒアゴニスト
WO2002083616A1 (fr) * 2001-04-10 2002-10-24 Sankyo Company, Limited DERIVE D'ACIDE GRAS φomega;-ARYLE α-SUBSTITUE
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US7220880B2 (en) 2002-06-19 2007-05-22 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314134D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
PT1458672E (pt) 2007-07-18
SI1458673T1 (sl) 2007-02-28
EP1458672A1 (de) 2004-09-22
MXPA04006003A (es) 2004-09-27
CY1106276T1 (el) 2011-10-12
US20050171204A1 (en) 2005-08-04
US7256307B2 (en) 2007-08-14
PL370673A1 (en) 2005-05-30
HK1068870A1 (en) 2005-05-06
HUP0402022A3 (en) 2009-06-29
CA2469302A1 (en) 2003-06-26
UA77987C2 (en) 2007-02-15
CY1106784T1 (el) 2012-05-23
TWI253444B (en) 2006-04-21
MXPA04006004A (es) 2004-09-27
EP1458673A1 (de) 2004-09-22
HUP0402133A3 (en) 2010-07-28
TW200410918A (en) 2004-07-01
TWI255807B (en) 2006-06-01
JP2006298924A (ja) 2006-11-02
PT1458673E (pt) 2006-12-29
SI1458672T1 (sl) 2007-10-31
HK1068604A1 (en) 2005-04-29
ATE363466T1 (de) 2007-06-15
DE60214594D1 (de) 2006-10-19
KR20040074092A (ko) 2004-08-21
HUP0402022A2 (hu) 2005-01-28
IS7309A (is) 2004-06-14
RU2300517C2 (ru) 2007-06-10
DK1458672T3 (da) 2007-09-17
ZA200404657B (en) 2005-08-29
TW200410925A (en) 2004-07-01
ZA200404658B (en) 2006-02-22
ES2271381T3 (es) 2007-04-16
BR0214986A (pt) 2004-12-14
HUP0402133A2 (hu) 2005-02-28
JP2005526704A (ja) 2005-09-08
JP3784804B2 (ja) 2006-06-14
NO20043164L (no) 2004-07-16
JP2005526011A (ja) 2005-09-02
UA77460C2 (en) 2006-12-15
WO2003051822A1 (en) 2003-06-26
CN100406427C (zh) 2008-07-30
US7514471B2 (en) 2009-04-07
NZ533274A (en) 2005-12-23
NO20043023L (no) 2004-07-15
WO2003051821A1 (en) 2003-06-26
RU2004116918A (ru) 2005-11-10
CN1896045A (zh) 2007-01-17
RU2004116917A (ru) 2005-11-10
AU2002352427A1 (en) 2003-06-30
ATE338743T1 (de) 2006-09-15
EP1458672B1 (de) 2007-05-30
AU2002366315A1 (en) 2003-06-30
AR038045A1 (es) 2004-12-22
DE60214594T2 (de) 2007-09-13
CN1293044C (zh) 2007-01-03
BR0214988A (pt) 2004-12-14
EP1458673B1 (de) 2006-09-06
IL162330A0 (en) 2005-11-20
JP2005336209A (ja) 2005-12-08
AR038047A1 (es) 2004-12-22
NZ533276A (en) 2006-04-28
US20050113362A1 (en) 2005-05-26
KR20040074094A (ko) 2004-08-21
PL370672A1 (en) 2005-05-30
CN1620423A (zh) 2005-05-25
DK1458673T3 (da) 2006-12-11
RU2303031C2 (ru) 2007-07-20
CN1620422A (zh) 2005-05-25
IS7313A (is) 2004-06-15
IL162331A0 (en) 2005-11-20
DE60220441T2 (de) 2008-01-24
JP3820249B2 (ja) 2006-09-13
MY132565A (en) 2007-10-31
ES2286310T3 (es) 2007-12-01
CA2470491A1 (en) 2003-06-26
SE0104334D0 (sv) 2001-12-19
IL162330A (en) 2009-06-15

Similar Documents

Publication Publication Date Title
DE60220441D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
ATE512594T1 (de) Verbesserung des zustandes älterer haustiere
CY2014003I1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
ATE296619T1 (de) Feste orale dosierungsform von simethicon
NO20030550D0 (no) 17<beta>-karbotioat 17<alfa>-arylkarbonyloksyandrostanderivat som anti-inflammatoriske midler
IS6709A (is) Fljótandi samsetningar metformíns
DE60143984D1 (de) Neue phenylalanin-derivate
DK1299729T3 (da) Tidlig diagnosticering af konformationelle sygdomme
EE200100395A (et) (S)-omeprasooli kaaliumisool
DE60008422D1 (de) Pour-on formulierungen
DK1441771T3 (da) Vandige proteinformuleringer med opreholdt frigivelse
EE200200701A (et) Kõrgkontsentreeritud stabiilsed meloksikaami lahused
NO20026209D0 (no) Endoparasitticidale midler for frivillig oralt inntak av dyr
ATE332903T1 (de) Kondensierte pyridoindolderivate
DK1764111T3 (da) Vaginalt indgivne anti-dysrytmi midler til behandling af uterin dysrytmi
ATE455754T1 (de) Arylsulfonamid-substituierte hydroxamsäure- derivate
DE60036093D1 (de) Antagonisten des gardos-kanals
DK1464641T3 (da) 4-phenylpiperazinyl-, -piperidinyl- og -tetrahydropyridylderivater som dopamin-D4-antagonister
DK1216032T3 (da) Orale formuleringer med kontrolleret frigivelse
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
NO20003799L (no) Innkorporering av kolesterol senkende midler i konfekt- dosisformer
ID30381A (id) Penggunaan arilalkanoilpiridazina
DE50310743D1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat
ITMI20020871A1 (it) Derivati alogenati dell'iperforina loro uso e formulazioni che li contengono

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee